Chronic Lymphocytic Leukemia

Treatment for Relapsed Chronic Lymphocytic Leukemia

Jordan Gauthier, MD, MSc, discussed the results presented at the 2018 ASH Annual for this clinical trial and where the research is headed for patients with CLL. He also highlights another promising combination for this patient population that was presented at the meeting as well.

A triplet regimen consisting of chlorambucil and rituximab in combination with an individualized dose of lenalidomide can potentially be used as a frontline treatment for patients with advanced chronic lymphocytic leukemia who are older or unfit for standard treatment with fludarabine, cyclophosphamide, and rituximab.

Chronic Lymphocytic Leukemia

Jordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.

Relapsed Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, discusses phase II findings with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in CLL.

Nicole Lamanna, MD, discusses the significance of the 3-year follow-up data from the MURANO trial in patients with relapsed/refractory chronic lymphocytic leukemia.

The combination of venetoclax with rituximab led to high rates of undetectable minimal residual disease for patients with relapsed/refractory chronic lymphoblastic leukemia. This was associated with a prolonged progression-free survival, according to a new analysis of a randomized trial presented at the 2018 ASH Annual Meeting.

The BTK inhibitor acalabrutinib demonstrated promising reponse rates in patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia, according to results from an open-label phase II trial.